| Dr Ivy Reyes Melgarejo, | |
|
1215 Pleasant St Ste 100, Des Moines, IA 50309-1409 | |
| (515) 336-6557 | |
| Not Available |
| Full Name | Dr Ivy Reyes Melgarejo |
|---|---|
| Gender | Female |
| Speciality | Nephrology |
| Experience | 13 Years |
| Location | 1215 Pleasant St Ste 100, Des Moines, Iowa |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518349992 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RN0300X | Internal Medicine - Nephrology | 48007 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ottumwa Dialysis | Ottumwa, IA | Dialysis facility |
| Unitypoint Health - Des Moines Iowa Methodist Medi | Des moines, IA | Hospital |
| Mahaska Health Partnership | Oskaloosa, IA | Hospital |
| Mercyone Des Moines Medical Center | Des moines, IA | Hospital |
| Wayne County Hospital | Corydon, IA | Hospital |
| Monroe County Hospital | Albia, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Kidney Physicians, P.c. | 7012806409 | 16 |
News Archive
Mobile Aspects, a leader in RFID enabled clinical process improvement systems, announced today that Novation, the health care contracting services company for VHA Inc., the University HealthSystem Consortium (UHC), and Provista, has awarded Mobile Aspects a three-year contract to supply radio frequency identification (RFID) inventory management systems to its member organizations.
A federal report predicts this $5 billion account created as part of the health law will be drained by 2012. In related news, one senator criticizes the program's handling. Also drawing criticism are exchange regulations, which advocates say could undermine the law's goal of expanding health insurance. Meanwhile, the Department of Health and Human Services finalized standards -; part of the administration's efforts to reduce health disparities -; to track factors that affect people's health.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.
In a clinical trial of over 48,000 post-menopausal women, a low-fat diet that includes increased consumption of fruits, vegetables and whole grains is not associated with weight gain over an average of 7.5 years, according to a study in the January 4 issue of JAMA: The Journal of the American Medical Association.
› Verified 9 days ago
| Entity Name | Broadlawns Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467447508 PECOS PAC ID: 3678466166 Enrollment ID: O20040206000913 |
News Archive
Mobile Aspects, a leader in RFID enabled clinical process improvement systems, announced today that Novation, the health care contracting services company for VHA Inc., the University HealthSystem Consortium (UHC), and Provista, has awarded Mobile Aspects a three-year contract to supply radio frequency identification (RFID) inventory management systems to its member organizations.
A federal report predicts this $5 billion account created as part of the health law will be drained by 2012. In related news, one senator criticizes the program's handling. Also drawing criticism are exchange regulations, which advocates say could undermine the law's goal of expanding health insurance. Meanwhile, the Department of Health and Human Services finalized standards -; part of the administration's efforts to reduce health disparities -; to track factors that affect people's health.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.
In a clinical trial of over 48,000 post-menopausal women, a low-fat diet that includes increased consumption of fruits, vegetables and whole grains is not associated with weight gain over an average of 7.5 years, according to a study in the January 4 issue of JAMA: The Journal of the American Medical Association.
› Verified 9 days ago
| Entity Name | Iowa Kidney Physicians, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1669427266 PECOS PAC ID: 7012806409 Enrollment ID: O20040312001298 |
News Archive
Mobile Aspects, a leader in RFID enabled clinical process improvement systems, announced today that Novation, the health care contracting services company for VHA Inc., the University HealthSystem Consortium (UHC), and Provista, has awarded Mobile Aspects a three-year contract to supply radio frequency identification (RFID) inventory management systems to its member organizations.
A federal report predicts this $5 billion account created as part of the health law will be drained by 2012. In related news, one senator criticizes the program's handling. Also drawing criticism are exchange regulations, which advocates say could undermine the law's goal of expanding health insurance. Meanwhile, the Department of Health and Human Services finalized standards -; part of the administration's efforts to reduce health disparities -; to track factors that affect people's health.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.
In a clinical trial of over 48,000 post-menopausal women, a low-fat diet that includes increased consumption of fruits, vegetables and whole grains is not associated with weight gain over an average of 7.5 years, according to a study in the January 4 issue of JAMA: The Journal of the American Medical Association.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ivy Reyes Melgarejo, 1215 Pleasant St Ste 100, Des Moines, IA 50309-1409 Ph: (515) 336-6557 | Dr Ivy Reyes Melgarejo, 1215 Pleasant St Ste 100, Des Moines, IA 50309-1409 Ph: (515) 336-6557 |
News Archive
Mobile Aspects, a leader in RFID enabled clinical process improvement systems, announced today that Novation, the health care contracting services company for VHA Inc., the University HealthSystem Consortium (UHC), and Provista, has awarded Mobile Aspects a three-year contract to supply radio frequency identification (RFID) inventory management systems to its member organizations.
A federal report predicts this $5 billion account created as part of the health law will be drained by 2012. In related news, one senator criticizes the program's handling. Also drawing criticism are exchange regulations, which advocates say could undermine the law's goal of expanding health insurance. Meanwhile, the Department of Health and Human Services finalized standards -; part of the administration's efforts to reduce health disparities -; to track factors that affect people's health.
Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation.
Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.
In a clinical trial of over 48,000 post-menopausal women, a low-fat diet that includes increased consumption of fruits, vegetables and whole grains is not associated with weight gain over an average of 7.5 years, according to a study in the January 4 issue of JAMA: The Journal of the American Medical Association.
› Verified 9 days ago
Dr. Joshua C Lukenbill, D.O. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant Street, Suite 100, Des Moines, IA 50309 Phone: 515-282-2921 Fax: 515-282-1035 | |
Dr. Akshay Mahesh Khatri, M.B.B.S., MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant St Ste 300, Des Moines, IA 50309 Phone: 515-241-4200 Fax: 515-241-4048 | |
Ravinder Dervesh, MD Nephrology Medicare: Accepting Medicare Assignments Practice Location: 411 Laurel St Ste 1225, Des Moines, IA 50314 Phone: 515-633-3770 Fax: 515-288-6713 | |
Mr. David Augusto Terrero Salcedo, M.D Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1221 Pleasant St Ste 300, Des Moines, IA 50309 Phone: 515-241-4200 Fax: 515-241-4048 | |
Tyler Mumm, DO Nephrology Medicare: Not Enrolled in Medicare Practice Location: 1111 6th Ave, Des Moines, IA 50314 Phone: 515-643-2261 Fax: 515-643-5802 | |
Bilal Hasan Baig, DO Nephrology Medicare: Medicare Enrolled Practice Location: 1200 Pleasant St, Des Moines, IA 50309 Phone: 515-241-6636 Fax: 515-241-4080 | |
Dr. Sean D Cunningham, M.D. Nephrology Medicare: Accepting Medicare Assignments Practice Location: 1215 Pleasant St, Ste 206, Des Moines, IA 50309 Phone: 515-875-9092 Fax: 515-875-9828 |